아마타 파마슈티컬스ARMP 주가

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2026, and provided a corporate update.

Armata Pharmaceuticals Q1 EPS $(3.16) Misses $(0.38) Estimate, Sales $789.000K Up From $491.000K YoY

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.16) per share which missed the analyst consensus estimate of $(0.38) by 731.58 percent. This is a 1480 percent decrease over losses of $(0.20) per share

[SCHEDULE 13D/A] SCHEDULE 13D/A

[10-Q] 분기 실적 — 10-Q

♻️ 재탕[8-K] 중대 사건 — 8-K

♻️ 재탕Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus ("S. aureus") multi-

Armata Pharmaceuticals Granted FDA's Fast Track Designation For AP-SA02 To Treat Bacterial Infections

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment

[8-K] 중대 사건 — FORM 8-K

Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in Communications Biology, a peer-reviewed journal from Nature Portfolio.

Armata Pharmaceutics Announces Publication Of Paper In 'Communications Biology,' A Peer-Reviewed Journal From Nature Portfolio

The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's multi-phage cocktail,